18F-DCFPyL PET/CT in the detection of prostate cancer at 60 and 120 minutes: Detection rate, image quality, activity kinetics, and biodistribution

Journal of Nuclear Medicine

Volumn 58, Issue 11, 2017, Pages 1797-1804

  Wondergem, Maurits ^a,b   Van Der Zant, Friso M ^a   Knol, Remco J J ^a   Lazarenko, Sergiy V ^a   Pruim, Jan ^b,c   De Jong, Igle J ^b  

^a Medical Centre Alkmaar   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

18F DCFPyL; Image acquisition; PET CT; Prostate cancer; Urology

Indexed keywords

2 [3 [1 CARBOXY 5 [(6 FLUOROPYRIDINE 3 CARBONYL)AMINO] PENTYL]UREIDO]PENTANEDIOIC ACID F 18; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TRACER; UNCLASSIFIED DRUG; 2-(3-(1-CARBOXY-5-((6-FLUOROPYRIDINE-3-CARBONYL)AMINO)PENTYL)UREIDO)PENTANEDIOIC ACID; LYSINE; PYRROLIDIN-3-YL-METHANESULFONIC ACID; PYRROLIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; UREA;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE; BLOOD; BONE LESION; BONE MARROW; CANCER DIAGNOSIS; CANCER STAGING; COHORT ANALYSIS; DUODENUM; HISTOPATHOLOGY; HUMAN; IMAGE QUALITY; KIDNEY; KINETICS; LIVER; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RADIOTHERAPY; RETROSPECTIVE STUDY; SEMINAL VESICLE; SIGNAL NOISE RATIO; SPLEEN; TIME FACTOR; TISSUE DISTRIBUTION; ANALOGS AND DERIVATIVES; DIAGNOSTIC IMAGING; IMAGE PROCESSING; INJECTION; METABOLISM; MIDDLE AGED; PILOT STUDY; PROCEDURES; PROSTATE TUMOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INJECTIONS; LYSINE; MALE; MIDDLE AGED; PILOT PROJECTS; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS; PYRROLIDINES; RADIOPHARMACEUTICALS; SIGNAL-TO-NOISE RATIO; TISSUE DISTRIBUTION; UREA;

EID: 85030861340     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.117.192658     Document Type: Article

References (36)

1. Jadvar H. Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/ CT: utility and limitations. Eur J Nucl Med Mol Imaging. 2013;40(suppl 1):S5–S10.
2. Evangelista L, Guttilla A, Zattoni F, Muzzio PC, Zattoni F. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol. 2013;63:1040–1048.
3. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528–539.
4. Pinto JT, Suffoletto BP, Berzin TM, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res. 1996;2:1445–1451.
5. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res. 1994;54:1807–1811.
6. Rajasekaran AK, Anilkumar G, Christiansen JJ. Is prostate-specific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol. 2005;288:C975–C981.
7. Sokoloff RL, Norton KC, Gasior CL, Marker KM, Grauer LS. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate. 2000;43:150–157.
8. Laidler P, Dulinska J, Lekka M, Lekki J. Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3. Arch Biochem Biophys. 2005;435:1–14.
9. Rajasekaran SA, Anilkumar G, Oshima E, et al. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell. 2003;14:4835–4845.
10. Elsässer-Beile U, Wolf P, Gierschner D, Buhler P, Schultze-Seemann W, Wetterauer U. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate. 2006;66:1359–1370.
11. Tagawa ST, Beltran H, Vallabhajosula S, et al. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer. 2010;116: 1075–1083.
12. Wolf P, Freudenberg N, Buhler P, et al. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate. 2010;70:562–569.
13. Regino CA, Wong KJ, Milenic DE, et al. Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen. Curr Radiopharm. 2009;2:9–17.
14. Foss CA, Mease RC, Fan H, et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res. 2005;11:4022–4028.
15. Mease RC, Dusich CL, Foss CA, et al. N-[N-[(S)-1,3-dicarboxypropyl]carba-moyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res. 2008;14:3036–3043.
16. Chen Y, Pullambhatla M, Foss CA, et al. 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pen tanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17:7645–7653.
17. Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11–20.
18. Eder M, Neels O, Muller M, et al. Novel preclinical and radiopharmaceutical aspects of [68Ga]ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals (Basel). 2014;7:779–796.
19. Bluemel C, Krebs M, Polat B, et al. 68Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18F-choline-PET/CT. Clin Nucl Med. 2016;41:515–521.
20. Szabo Z, Mena E, Rowe SP, et al. Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17:565–574.
21. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–495.
22. Herrmann K, Bluemel C, Weineisen M, et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med. 2015;56:855–861.
23. Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697–1705.
24. Afshar-Oromieh A, Hetzheim H, Kubler W, et al. Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016;43:1611–1620.
25. Afshar-Oromieh A, Sattler LP, Mier W, et al. The clinical impact of additional late PET/CT imaging with 68Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer. J Nucl Med. 2017;58:750–755.
26. Rowe SP, Macura KJ, Mena E, et al. PSMA-based [18F]DCFPyL PET/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer. Mol Imaging Biol. 2016;18:411–419.
27. Bouvet V, Wuest M, Jans HS, et al. Automated synthesis of [18F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models. EJNMMI Res. 2016;6:40-016-0195-6.
28. Bismuth H. Surgical anatomy and anatomical surgery of the liver. World J Surg. 1982;6:3–9.
29. Sahlmann CO, Meller B, Bouter C, et al. Biphasic 68Ga-PSMA-HBED-CC-PET/ CT in patients with recurrent and high-risk prostate carcinoma. Eur J Nucl Med Mol Imaging. 2016;43:898–905.
30. Verburg FA, Kuhl CK, Pietsch H, Palmowski M, Mottaghy FM, Behrendt FF. The influence of different contrast medium concentrations and injection protocols on quantitative and clinical assessment of FDG-PET/CT in lung cancer. Eur J Radiol. 2013;82:e617–e622.
31. Aschoff P, Plathow C, Beyer T, et al. Multiphase contrast-enhanced CT with highly concentrated contrast agent can be used for PET attenuation correction in integrated PET/CT imaging. Eur J Nucl Med Mol Imaging. 2012;39:316–325.
32. Mawlawi O, Erasmus JJ, Munden RF, et al. Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation. AJR. 2006;186:308–319.
33. Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50(suppl 1):11S–20S.
34. Herlemann A, Wenter V, Kretschmer A, et al. 68Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol. 2016;70:553–557.
35. Rauscher I, Maurer T, Beer AJ, et al. Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphade-nectomy. J Nucl Med. 2016;57:1713–1719.
36. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209.